FGFR1_HUMAN,T15D,0.847,Gain of Loop (Pr = 0.27 | P = 0.03); Altered Signal peptide (Pr = 0.18 | P = 3.8e-04), ELME000041|ELME000052|ELME000147|ELME000333,-
FGFR1_HUMAN,T15R,0.892,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.20 | P = 2.9e-04), ELME000041|ELME000052|ELME000062|ELME000333,-
FGFR1_HUMAN,T15V,0.803,Altered Signal peptide (Pr = 0.18 | P = 3.5e-04), ELME000041|ELME000052|ELME000333,-
FGFR1_HUMAN,T17S,0.561,Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03); Altered Signal peptide (Pr = 0.19 | P = 3.3e-04), ELME000052|ELME000053|ELME000063,-
FGFR1_HUMAN,T20G,0.752,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Signal peptide (Pr = 0.19 | P = 3.6e-04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,T20L,0.727,Altered Signal peptide (Pr = 0.24 | P = 1.5e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,P23A,0.488,-,-,-
FGFR1_HUMAN,S24P,0.645,Loss of Loop (Pr = 0.27 | P = 0.03); Gain of B-factor (Pr = 0.26 | P = 0.02); Altered Signal peptide (Pr = 0.20 | P = 3.0e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220,-
FGFR1_HUMAN,P25L,0.601,Altered Signal peptide (Pr = 0.36 | P = 3.4e-05); Loss of Intrinsic disorder (Pr = 0.35 | P = 0.04); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q30 (Pr = 0.07 | P = 0.02), ELME000005|ELME000051|ELME000062|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220|ELME000239,-
FGFR1_HUMAN,T26S,0.521,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Signal peptide (Pr = 0.18 | P = 4.0e-04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q30 (Pr = 0.06 | P = 0.02), ELME000005|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220|ELME000239|PS00006,-
FGFR1_HUMAN,E29P,0.823,Gain of O-linked glycosylation at T26 (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.08 | P = 0.02), ELME000064|ELME000145|ELME000220|PS00006,-
FGFR1_HUMAN,Q30A,0.398,-,-,-
FGFR1_HUMAN,A31G,0.335,-,-,-
FGFR1_HUMAN,A31L,0.534,Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.08 | P = 0.02), None,-
FGFR1_HUMAN,A36T,0.140,-,-,-
FGFR1_HUMAN,V45A,0.256,-,-,-
FGFR1_HUMAN,P47S,0.302,-,-,-
FGFR1_HUMAN,S63I,0.572,Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000193|ELME000233|ELME000335,-
FGFR1_HUMAN,D69G,0.821,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.21 | P = 0.03); Loss of Proteolytic cleavage at D69 (Pr = 0.12 | P = 0.03), ELME000193,-
FGFR1_HUMAN,V71A,0.357,-,-,-
FGFR1_HUMAN,S76G,0.340,-,-,-
FGFR1_HUMAN,Q89R,0.050,-,-,-
FGFR1_HUMAN,Q89W,0.261,-,-,-
FGFR1_HUMAN,V92G,0.326,-,-,-
FGFR1_HUMAN,V102M,0.187,-,-,-
FGFR1_HUMAN,D128E,0.458,-,-,-
FGFR1_HUMAN,T141A,0.159,-,-,-
FGFR1_HUMAN,T141M,0.165,-,-,-
FGFR1_HUMAN,M149R,0.394,-,-,-
FGFR1_HUMAN,S181N,0.334,-,-,-
FGFR1_HUMAN,N185S,0.227,-,-,-
FGFR1_HUMAN,M276V,0.277,-,-,-
FGFR1_HUMAN,V308D,0.897,Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000020|ELME000083|ELME000120|ELME000182,-
FGFR1_HUMAN,E324S,0.800,Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Gain of Ubiquitylation at K321 (Pr = 0.15 | P = 0.05), ELME000065|ELME000147|ELME000335,-
FGFR1_HUMAN,H327T,0.701,Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Gain of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000122|ELME000137|ELME000334|ELME000335|PS00005,-
FGFR1_HUMAN,V331I,0.763,Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04); Gain of Strand (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.17 | P = 0.04); Gain of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000334|PS00001,-
FGFR1_HUMAN,T340M,0.834,Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.26 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000120|ELME000182,-
FGFR1_HUMAN,L342F,0.807,Altered Metal binding (Pr = 0.27 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Altered Ordered interface (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000120|ELME000182|ELME000337,-
FGFR1_HUMAN,A343S,0.772,Altered Metal binding (Pr = 0.31 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Gain of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.10 | P = 0.04), ELME000053|ELME000063|ELME000085|ELME000239,-
FGFR1_HUMAN,S346G,0.811,Altered Metal binding (Pr = 0.34 | P = 9.6e-03); Altered Transmembrane protein (Pr = 0.26 | P = 8.7e-04); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.08 | P = 0.05), ELME000053|ELME000239|PS00008,-
FGFR1_HUMAN,S350A,0.516,Altered Transmembrane protein (Pr = 0.27 | P = 5.5e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000053|ELME000063|ELME000239,-
FGFR1_HUMAN,E360P,0.715,Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04), ELME000064|ELME000220|ELME000333|ELME000341|PS00006,-
FGFR1_HUMAN,E364D,0.199,-,-,-
FGFR1_HUMAN,V368G,0.380,-,-,-
FGFR1_HUMAN,T382A,0.375,-,-,-
FGFR1_HUMAN,V391A,0.257,-,-,-
FGFR1_HUMAN,V391L,0.191,-,-,-
FGFR1_HUMAN,T428Q,0.822,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Loss of Phosphorylation at T428 (Pr = 0.30 | P = 0.02); Loss of O-linked glycosylation at T428 (Pr = 0.20 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Proteolytic cleavage at D432 (Pr = 0.13 | P = 0.02), ELME000051|ELME000053|ELME000146,-
FGFR1_HUMAN,A435T,0.147,-,-,-
FGFR1_HUMAN,R477K,0.562,, ELME000146,-
FGFR1_HUMAN,K504R,0.328,-,-,-
FGFR1_HUMAN,S518A,0.295,-,-,-
FGFR1_HUMAN,D554G,0.648,Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Metal binding (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Gain of Catalytic site at C551 (Pr = 0.13 | P = 0.03), ELME000202,-
FGFR1_HUMAN,S588G,0.138,-,-,-
FGFR1_HUMAN,Q594L,0.503,Loss of Loop (Pr = 0.27 | P = 0.03), ELME000240,-
FGFR1_HUMAN,V601I,0.254,-,-,-
FGFR1_HUMAN,N635S,0.471,-,-,-
FGFR1_HUMAN,L662A,0.899,Altered Stability (Pr = 0.55 | P = 1.4e-03); Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
FGFR1_HUMAN,A671G,0.762,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.05), None,-
FGFR1_HUMAN,E728D,0.615,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at Y730 (Pr = 0.23 | P = 0.02); Altered Metal binding (Pr = 0.06 | P = 0.03); Loss of N-linked glycosylation at N724 (Pr = 0.02 | P = 0.03); Loss of N-terminal acetylation at M732 (Pr = 0.02 | P = 8.1e-03), ELME000052|ELME000063|ELME000070,-
FGFR1_HUMAN,H738N,0.704,Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Allosteric site at W737 (Pr = 0.25 | P = 0.01); Gain of Disulfide linkage at C736 (Pr = 0.12 | P = 0.04), None,-
FGFR1_HUMAN,M771V,0.068,-,-,-
FGFR1_HUMAN,T783A,0.197,-,-,-
FGFR1_HUMAN,A812I,0.139,-,-,-
FGFR1_HUMAN,R821P,0.496,-,-,-
FGFR1_HUMAN,E294K,0.856,Loss of Strand (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Stability (Pr = 0.11 | P = 0.03); Loss of N-linked glycosylation at N296 (Pr = 0.08 | P = 0.02), ELME000146,-
FGFR1_HUMAN,L624P,0.954,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of Allosteric site at R627 (Pr = 0.29 | P = 3.1e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.28 | P = 2.7e-03); Altered Metal binding (Pr = 0.15 | P = 0.02); Gain of Catalytic site at R627 (Pr = 0.12 | P = 0.03), PS00109,-
FGFR1_HUMAN,C341W,0.973,Altered Metal binding (Pr = 0.53 | P = 3.4e-03); Altered Ordered interface (Pr = 0.30 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.5e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Disulfide linkage at C341 (Pr = 0.24 | P = 9.7e-03); Altered Stability (Pr = 0.09 | P = 0.04), ELME000120|ELME000147|ELME000182,-
FGFR1_HUMAN,D623Y,0.907,Altered DNA binding (Pr = 0.36 | P = 7.9e-04); Altered Disordered interface (Pr = 0.34 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 3.0e-03); Gain of Allosteric site at R627 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 2.8e-03); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Catalytic site at R627 (Pr = 0.12 | P = 0.03), ELME000182|PS00109,-
FGFR1_HUMAN,M161T,0.829,Loss of SUMOylation at K160 (Pr = 0.27 | P = 5.1e-03); Gain of B-factor (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,C101F,0.963,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Stability (Pr = 0.26 | P = 7.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 2.0e-03); Loss of Disulfide linkage at C101 (Pr = 0.23 | P = 0.01); Gain of O-linked glycosylation at T103 (Pr = 0.19 | P = 0.02), ELME000053|ELME000120|ELME000336|PS00008,-
FGFR1_HUMAN,L342S,0.901,Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 5.5e-04); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Disulfide linkage at C341 (Pr = 0.20 | P = 0.02); Altered Stability (Pr = 0.17 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.09 | P = 0.05); Gain of GPI-anchor amidation at N345 (Pr = 0.01 | P = 0.03), ELME000053|ELME000085|ELME000120|ELME000182,-
FGFR1_HUMAN,D129A,0.512,Loss of B-factor (Pr = 0.34 | P = 1.6e-03); Loss of Loop (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.7e-03); Gain of Proteolytic cleavage at D133 (Pr = 0.20 | P = 2.1e-03); Altered Metal binding (Pr = 0.13 | P = 0.03), None,-
FGFR1_HUMAN,I216V,0.215,-,-,-
FGFR1_HUMAN,S450F,0.795,Loss of Intrinsic disorder (Pr = 0.62 | P = 1.1e-03); Gain of Strand (Pr = 0.30 | P = 2.9e-03); Loss of Phosphorylation at T454 (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of ADP-ribosylation at R448 (Pr = 0.20 | P = 0.04), ELME000053|ELME000062|ELME000063|ELME000197|ELME000336,-
FGFR1_HUMAN,G260E,0.848,Gain of Relative solvent accessibility (Pr = 0.34 | P = 1.8e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 2.9e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.9e-04); Gain of N-linked glycosylation at N264 (Pr = 0.17 | P = 4.3e-03), PS00008,-
FGFR1_HUMAN,G97S,0.874,Gain of Intrinsic disorder (Pr = 0.36 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.23 | P = 0.05); Loss of Disulfide linkage at C101 (Pr = 0.18 | P = 0.03); Loss of Proteolytic cleavage at D95 (Pr = 0.12 | P = 0.03), ELME000085|ELME000147|ELME000239|ELME000337|PS00008,-
FGFR1_HUMAN,S346C,0.851,Altered Transmembrane protein (Pr = 0.33 | P = 5.4e-05); Altered Metal binding (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of Disulfide linkage at C341 (Pr = 0.22 | P = 0.01), ELME000053|ELME000239|PS00008,-
FGFR1_HUMAN,I538V,0.505,Altered Coiled coil (Pr = 0.27 | P = 0.01), None,-
FGFR1_HUMAN,V688L,0.590,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 2.9e-03), None,-
FGFR1_HUMAN,C178S,0.960,Altered Metal binding (Pr = 0.57 | P = 2.5e-03); Gain of Intrinsic disorder (Pr = 0.49 | P = 1.9e-03); Loss of Disulfide linkage at C178 (Pr = 0.42 | P = 5.1e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of B-factor (Pr = 0.28 | P = 8.3e-03); Altered Transmembrane protein (Pr = 0.27 | P = 8.8e-04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of O-linked glycosylation at S181 (Pr = 0.26 | P = 7.9e-03), ELME000063|ELME000136|ELME000159,-
FGFR1_HUMAN,F747L,0.857,Loss of Loop (Pr = 0.26 | P = 0.05); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000062|ELME000231|PS00005,-
FGFR1_HUMAN,S96P,0.816,Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C101 (Pr = 0.18 | P = 0.03); Loss of Proteolytic cleavage at D95 (Pr = 0.14 | P = 0.02), ELME000085|ELME000155|ELME000239,-
FGFR1_HUMAN,R448W,0.678,Loss of Intrinsic disorder (Pr = 0.64 | P = 6.0e-04); Gain of Strand (Pr = 0.30 | P = 1.9e-03); Loss of ADP-ribosylation at R448 (Pr = 0.27 | P = 7.8e-03), ELME000053|ELME000062|ELME000063,-
FGFR1_HUMAN,A167S,0.522,Gain of Strand (Pr = 0.29 | P = 5.4e-03); Gain of Acetylation at K172 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000065|ELME000173,-
FGFR1_HUMAN,P722S,0.866,Altered DNA binding (Pr = 0.22 | P = 0.01); Gain of Disulfide linkage at C725 (Pr = 0.09 | P = 0.05); Gain of N-linked glycosylation at N724 (Pr = 0.02 | P = 0.03), ELME000053|ELME000336,-
FGFR1_HUMAN,P700L,0.910,Altered Ordered interface (Pr = 0.28 | P = 5.2e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.12 | P = 0.03), ELME000136|ELME000155|ELME000159|ELME000336,-
FGFR1_HUMAN,G487D,0.921,Gain of Helix (Pr = 0.30 | P = 6.1e-03); Loss of Strand (Pr = 0.27 | P = 0.01), PS00107,-
FGFR1_HUMAN,V116I,0.284,-,-,-
FGFR1_HUMAN,I639T,0.910,Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.3e-03); Gain of Allosteric site at F642 (Pr = 0.27 | P = 6.1e-03); Altered Metal binding (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02); Gain of Ubiquitylation at K638 (Pr = 0.15 | P = 0.04), None,-
FGFR1_HUMAN,R646W,0.929,Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Helix (Pr = 0.27 | P = 0.05); Loss of Allosteric site at F642 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.17 | P = 9.8e-03), ELME000328,-
FGFR1_HUMAN,D224H,0.925,Altered Metal binding (Pr = 0.47 | P = 5.7e-03); Altered Transmembrane protein (Pr = 0.32 | P = 5.8e-05); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of N-linked glycosylation at N227 (Pr = 0.17 | P = 4.7e-03), PS00005,-
FGFR1_HUMAN,S3A,0.462,-,-,-
FGFR1_HUMAN,W4R,0.846,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.23 | P = 0.02); Altered Signal peptide (Pr = 0.21 | P = 5.1e-04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000102|ELME000137|PS00005,-
FGFR1_HUMAN,K5R,0.309,-,-,-
FGFR1_HUMAN,K5S,0.480,-,-,-
FGFR1_HUMAN,C6I,0.483,-,-,-
FGFR1_HUMAN,C6L,0.631,Altered Disordered interface (Pr = 0.26 | P = 0.01); Altered Signal peptide (Pr = 0.20 | P = 6.2e-04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.2e-03), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,C6S,0.371,-,-,-
FGFR1_HUMAN,C6T,0.511,Altered Disordered interface (Pr = 0.29 | P = 9.2e-03); Altered Signal peptide (Pr = 0.18 | P = 7.7e-04); Gain of N-terminal acetylation at M1 (Pr = 0.03 | P = 4.7e-03), ELME000063|ELME000106|ELME000137|ELME000146,-
